<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.1 plus MathML 2.0//EN" "http://www.w3.org/Math/DTD/mathml2/xhtml-math11-f.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" lang="en-US">
<head profile="http://dublincore.org/documents/dcmi-terms/">
<meta name="robots" content="noindex, nofollow"></meta>
<meta name="viewport" content="width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.5, user-scalable=yes"></meta>
<style>
    table { border-collapse:collapse; border-spacing:0; empty-cells:show }
    td, th { vertical-align:top; font-size:12pt;}
    h1, h2, h3, h4, h5, h6 { clear:both;}
    ol, ul { margin:0; padding:0;}
    li { list-style: none; margin:0; padding:0;}
    span.footnodeNumber { padding-right:1em; }
    span.annotation_style_by_filter { font-size:95%; font-family:-apple-system, BlinkMacSystemFont, "PingFang SC", "Helvetica Neue", "Microsoft YaHei", sans-serif; background-color:#fff000;  margin:0; border:0; padding:0;  }
    span.heading_numbering { margin-right: 0.8rem; }* { margin:0;}
    .P1 { border-bottom-width:0.0399cm; border-bottom-style:double; border-bottom-color:#808080; border-left-style:none; border-right-style:none; border-top-style:none; color:#000000; font-size:14pt; margin-bottom:0.499cm; margin-top:0cm; padding:0cm; font-family:-apple-system, BlinkMacSystemFont, "PingFang SC", "Helvetica Neue", "Microsoft YaHei", sans-serif; writing-mode:horizontal-tb; direction:ltr;}
    .P10 { color:#000000; font-size:14pt; font-family:-apple-system, BlinkMacSystemFont, "PingFang SC", "Helvetica Neue", "Microsoft YaHei", sans-serif; writing-mode:horizontal-tb; direction:ltr;}
    .P11 { color:#000000; font-size:18pt; font-family:-apple-system, BlinkMacSystemFont, "PingFang SC", "Helvetica Neue", "Microsoft YaHei", sans-serif; writing-mode:horizontal-tb; direction:ltr;}
    .P12 { color:#666666; font-size:13pt; font-family:-apple-system, BlinkMacSystemFont, "PingFang SC", "Helvetica Neue", "Microsoft YaHei", sans-serif; writing-mode:horizontal-tb; direction:ltr;}
    .P13 { color:#000000; font-size:12pt; font-family:'Liberation Serif'; writing-mode:horizontal-tb; direction:ltr;}
    .P14 { color:#808080; font-size:14pt; font-family:-apple-system, BlinkMacSystemFont, "PingFang SC", "Helvetica Neue", "Microsoft YaHei", sans-serif; writing-mode:horizontal-tb; direction:ltr;background-color:#dddddd; }
    .P15 { color:#b2b2b2; font-size:10pt; line-height:115%; margin-bottom:0.247cm; margin-top:0cm; font-family:-apple-system, BlinkMacSystemFont, "PingFang SC", "Helvetica Neue", "Microsoft YaHei", sans-serif; writing-mode:horizontal-tb; direction:ltr;font-style:italic; }
    .P2 { border-bottom-width:0.0399cm; border-bottom-style:double; border-bottom-color:#808080; border-left-style:none; border-right-style:none; border-top-style:none; color:#000000; font-size:6pt; margin-bottom:0.499cm; margin-top:0cm; padding:0cm; font-family:-apple-system, BlinkMacSystemFont, "PingFang SC", "Helvetica Neue", "Microsoft YaHei", sans-serif; writing-mode:horizontal-tb; direction:ltr;}
    .P3 { color:#000000; font-size:14pt; font-family:-apple-system, BlinkMacSystemFont, "PingFang SC", "Helvetica Neue", "Microsoft YaHei", sans-serif; writing-mode:horizontal-tb; direction:ltr;}
    .P4 { color:#000000; font-size:14pt; font-family:-apple-system, BlinkMacSystemFont, "PingFang SC", "Helvetica Neue", "Microsoft YaHei", sans-serif; writing-mode:horizontal-tb; direction:ltr;}
    .P5 { color:#000000; font-size:14pt; font-family:-apple-system, BlinkMacSystemFont, "PingFang SC", "Helvetica Neue", "Microsoft YaHei", sans-serif; writing-mode:horizontal-tb; direction:ltr;}
    .P6 { color:#000000; font-size:14pt; font-family:-apple-system, BlinkMacSystemFont, "PingFang SC", "Helvetica Neue", "Microsoft YaHei", sans-serif; writing-mode:horizontal-tb; direction:ltr;}
    .P7 { color:#000000; font-size:14pt; font-family:-apple-system, BlinkMacSystemFont, "PingFang SC", "Helvetica Neue", "Microsoft YaHei", sans-serif; writing-mode:horizontal-tb; direction:ltr;}
    .P8 { color:#000000; font-size:14pt; font-family:-apple-system, BlinkMacSystemFont, "PingFang SC", "Helvetica Neue", "Microsoft YaHei", sans-serif; writing-mode:horizontal-tb; direction:ltr;}
    .P9 { color:#000000; font-size:14pt; font-family:-apple-system, BlinkMacSystemFont, "PingFang SC", "Helvetica Neue", "Microsoft YaHei", sans-serif; writing-mode:horizontal-tb; direction:ltr;}
    .Standard { color:#000000; font-size:12pt; font-family:'Liberation Serif'; writing-mode:horizontal-tb; direction:ltr;}
    .Internet_20_link { font-size:14pt; color:#000080; text-decoration:underline; }
    .T10 { color:#808080; font-family:-apple-system, BlinkMacSystemFont, "PingFang SC", "Helvetica Neue", "Microsoft YaHei", sans-serif; font-size:14pt; }
    .T11 { color:#808080; font-family:-apple-system, BlinkMacSystemFont, "PingFang SC", "Helvetica Neue", "Microsoft YaHei", sans-serif; font-size:14pt; }
    .T2 { color:#666666; font-family:-apple-system, BlinkMacSystemFont, "PingFang SC", "Helvetica Neue", "Microsoft YaHei", sans-serif; font-size:13pt; }
    .T21 { background-color:#ffffa6; }
    .T25 { background-color:#ffd8ce; }
    .T29 { background-color:#d0eaff; }
    .T3 { color:#666666; font-family:-apple-system, BlinkMacSystemFont, "PingFang SC", "Helvetica Neue", "Microsoft YaHei", sans-serif; font-size:13pt; }
    .T30 { background-color:#d0eaff; }
    .T31 { background-color:#d0eaff; }
    .T32 { background-color:#c4ffb1; }
    .T36 { background-color:#f3d1ff; }
    .T9 { color:#808080; font-family:-apple-system, BlinkMacSystemFont, "PingFang SC", "Helvetica Neue", "Microsoft YaHei", sans-serif; font-size:14pt; }
    /* ODF styles with no properties representable as CSS:
    .T1 .T12 .T13 .T4 .T5 .T7 .T8  { } */
</style>
</head>

<div style="position: fixed;text-align: center;width: 100%;background: #ededed;font-size: 12px;color: hsl(0deg 0% 50%);box-shadow: 0px 0px 15px;font-weight: bold;letter-spacing: 3px;font-style: italic;"><a style="font-style: initial;">📰</a>FAMILY-SHARING WEEKLY<div style="font-size: 10px;font-weight:100;">20220612 ISSUE #19</div></div>

<body style="max-width: 100%;margin: 48px 15px 15px 15px; word-break: break-word; line-height:18pt;">

<p class="P11"><span class="T4">12名直肠癌患者在一款新</span>药的临床实验中被全部治愈</p><p class="P1"> </p><p class="Standard"><span class="T2">稿源：</span><a href="https://www.foxnews.com/lifestyle/rectal-cancer-drug-trial-dostarlimab-cure" class="Internet_20_link"><span class="T3">(</span></a><a href="https://www.foxnews.com/lifestyle/rectal-cancer-drug-trial-dostarlimab-cure" class="Internet_20_link"><span class="T2">美国</span></a><a href="https://www.foxnews.com/lifestyle/rectal-cancer-drug-trial-dostarlimab-cure" class="Internet_20_link"><span class="T3">)福克斯新闻</span></a></p><p class="P12">发布时间：<span class="T1">2022-06-10 13:14  EDT</span></p><p class="P12">翻译/编辑：PH<span class="T1">0</span></p><p class="P1"> </p><p class="P4"> </p><p class="P5">      原标题：报告称一款名为“多斯达利马普”（Dostarlimab，音译）的实验性直肠癌药物治愈了全部参与实验的患者</p><p class="P5"> </p><p class="P6">      “多斯达利马普”的这项临床实验由<span class="T30">“纪念斯隆凯特林”癌症中心</span>（Memorial Sloan Kettering Cancer Center，一家专注癌症研究和治疗的医院）主导，共有<span class="T29">12名直肠癌患者参与</span><span class="T5">。</span></p><p class="P3"> </p><p class="P3">      <span class="T32">这项小规模临床实验表明，直肠癌是有可能被治愈的。</span>该实验的相关论文已于上周日在《新英格兰医学杂志》（the New England Journal of Medicine）上发表。</p><p class="P3"> </p><p class="P7">      根据实验论文的记载，<span class="T30">参与实验的患者每</span><span class="T31">3</span><span class="T30">周服用一次“多斯达利马普”，持续用药</span><span class="T31">6</span><span class="T30">个月，后续再接受半年的跟踪治疗（follow-up treatment）。</span>在跟踪治疗结束后，<span class="T21">没有任何患者复查出癌症病症。甚至部分患者经过两年的观察也没有出现癌症复发。</span></p><p class="P3"> </p><p class="P8">      据美国癌症协会（The American Cancer Society）预测，<span class="T7">2022年直肠癌新增患者将达44850例。同时，</span>结直肠癌（Colorectal cancer）也是美国癌症死亡的第二大主因。该协会预计今年因结直肠癌死亡的人数可能达到<span class="T12">52580人。</span></p><p class="P8"> </p><p class="P9">      据“纪念斯隆凯特林”癌症中心的新闻稿介绍，<span class="T25">参与此次临床实验的患者都存在一种被称为错配修复缺陷（mismatch repair-deficient，MMRd）的特定基因导致的肿瘤。</span>一般存在这种肿瘤情况的的直肠癌患者在<span class="T13">5%到10%之间。</span></p><p class="P8"> </p><p class="P8">      新闻稿还提到，<span class="T21">此次临床实验的参与者均无需接受放射、手术或化学治疗（None of the clinical trial patients required radiation, surgery or chemotherapy）。</span></p><p class="P3"> </p><p class="P3">      实验论文的作者之一，“纪念斯隆凯特林”癌症中心肿瘤科医师Dr. Luis Diaz, Jr.表示“相关结果真的令人激动。”“我认为这对患者来说是意义重大的。”</p><p class="P3"> </p><p class="P3">      对于现有成果的乐观表现，论文作者也明确提到<span class="T25">“有必要进行更长时间的随访来评估这一成果的是否持续有效。”</span></p><p class="P3"> </p><p class="P3">      在接下来的临床试验中，研究人员会继续招募（enroll）存在错配修复缺陷（MMRd）肿瘤的直肠癌患者。</p><p class="P3"> </p><p class="P10">       纪念斯隆凯特林”癌症中心同时也在研究药物“多斯达利马普”<span class="T36">是否有可能扩展应用到其它类型的、同样伴有错配修复缺陷（MMRd）肿瘤的癌症病患，如胃癌、前列腺或胰腺癌。</span></p><p class="P3"> </p><p class="P3"> </p><p class="P3">稿件原文（英语）：<a href="https://www.foxnews.com/lifestyle/rectal-cancer-drug-trial-dostarlimab-cure" class="Internet_20_link">https://www.foxnews.com/lifestyle/rectal-cancer-drug-trial-dostarlimab-cure</a></p><p class="P3"> </p><p class="P3">该临床实验关联的论文原文（英语）：<a href="https://doi.org/10.1056/NEJMoa2201445" class="Internet_20_link">https://doi.org/10.1056/NEJMoa2201445</a></p><p class="P3"> </p><p class="P2"> </p><p class="P14">批注, <span class="T8">PH, 20220612:</span></p><p class="P13"><span class="T9">①”结直肠癌“也称大肠癌，是结肠或直肠部位癌症的通称。详细的人体消化系统结构示意见图：</span><a href="https://gd1.alicdn.com/imgextra/i4/0/O1CN01WiX4h91fdKDxgM86l_!!0-item_pic.jpg" class="Internet_20_link">《人体消化系统结构概观示意图》</a><span class="T10"> </span><p class="P13"><span class="T9">②该临床实验论文中展示的</span><a href="./p6_p1.jpeg" class="Internet_20_link">“病例2的病灶变化多技术检查影像”对比图</a><span class="T11">。</span></p></p><p class="P2"> </p><p class="P15">Tags: 前瞻 医学 临床 药物 医药 实验 癌症 治疗 研究 </p></body><script src="/js/watermark.js"></script><script type="text/javascript">var now = getNow();<!-- watermark({"watermark_txt":"Family-sharing Weekly "+now}); -->watermark({"watermark_txt":"此为课内研学演示 不可外转或商用"});</script></html>
